Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome
Artikel i vetenskaplig tidskrift, 2020

Background Aloe barbadensis Mill. (Aloe) with potential prebiotic effects has been suggested to reduce symptoms in patients with irritable bowel syndrome (IBS). We therefore aimed to determine the effects of an Aloe extract on symptoms of IBS, and evaluate whether effects may be mediated by fecal microbiota and metabolites in a randomized, double-blind, controlled trial. Methods Patient with IBS diagnosed according to the ROME III criteria (all subtypes), received Aloe or control treatment (inulin) for 4 weeks. IBS Symptom Severity Score (IBS-SSS) was assessed, and fecal samples collected before and at end of treatment. Fecal microbiota composition and metabolomic profile were determined. Key results In total, 160 IBS patients completed the study. The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62). The frequency of responders (IBS-SSS reduction >= 50) did not differ between Aloe treatment (n = 33, 39%) and control (n = 34, 45%) (P = .49). However, fecal microbiota and metabolite profiles differed between Aloe, but not control treatment responders and non-responders both before and after treatment. Conclusion In a mixed group of IBS patients, Aloe was not superior to control treatment, although it showed potential to reduce IBS symptom severity in subsets of IBS patients which could be predicted by fecal microbiota and metabolite profiles. ClinicalTrials.gov no: NCT01400048.

fecal metabolites



gastrointestinal microbiota

gastrointestinal symptoms

irritable bowel syndrome


Bani Ahluwalia

Göteborgs universitet

Calmino Group AB

Maria K. Magnusson

Göteborgs universitet

Lena Bohn

Göteborgs universitet

Calmino Group AB

Stine Storsrud

Göteborgs universitet

Fredrik Larsson

Calmino Group AB

Otto Savolainen

Chalmers, Biologi och bioteknik, Systembiologi

Alastair Ross


Chalmers, Biologi och bioteknik, Livsmedelsvetenskap

Magnus Simren

Göteborgs universitet

The University of North Carolina at Chapel Hill

Lena Ohman

Göteborgs universitet

Neurogastroenterology and Motility

1350-1925 (ISSN) 13652982 (eISSN)

Vol. 32 8 e13860







Mer information

Senast uppdaterat